This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joseph, R. Articles by Welch, K. M. Search for Related Content PubMed PubMed Citation Articles by Joseph, R. Articles by Welch, K. M.

Stroke, Vol 20, 38-44, Copyright © 1989 by American Heart Association

ARTICLES

Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents

R Joseph, G D'Andrea, SB Oster and KM Welch
Department of Neurology, Henry Ford Hospital, Detroit, Michigan 48202.

We studied platelet function in whole blood, a situation that better reflects the in vivo state, from 85 patients with acute ischemic stroke and from 19 healthy controls. Patients receiving no antithrombotic drugs demonstrated increased platelet dense body secretion without an associated increase in platelet aggregation, thus raising the possibility that dense body secretion may be of separate importance in cerebral infarction. Our results also suggest that dense body secretion may occur independently of aggregation. Heparin and heparin plus warfarin were ineffective in reducing the high level of dense body secretion seen in acute cerebral infarction, whereas treatment with aspirin plus dipyridamole inhibited both dense body secretion and platelet aggregation. It seems worthwhile to investigate the usefulness of antiplatelet drugs in the treatment of acute ischemic stroke wherein clinical outcome is correlated with the extent of suppression of platelet dense body secretion.

This article has been cited by other articles:

				I. Kriszbacher, M. Koppan, J. Bodis, H.-K. Yip, S.-S. Chen, and M.-C. Chen Aspirin for Stroke Prevention Taken in the Evening? * Response: Stroke, December 1, 2004; 35(12): 2760 - 2762. [Full Text] [PDF]

				H.-K. Yip, S.-S. Chen, J. S. Liu, H.-W. Chang, Y.-F. Kao, M.-Y. Lan, Y.-Y. Chang, S.-L. Lai, W.-H. Chen, and M.-C. Chen Serial Changes in Platelet Activation in Patients After Ischemic Stroke: Role of Pharmacodynamic Modulation Stroke, July 1, 2004; 35(7): 1683 - 1687. [Abstract] [Full Text] [PDF]

				L. Marquardt, A. Ruf, U. Mansmann, R. Winter, M. Schuler, F. Buggle, H. Mayer, and A. J. Grau Course of Platelet Activation Markers After Ischemic Stroke Stroke, November 1, 2002; 33(11): 2570 - 2574. [Abstract] [Full Text] [PDF]

				J. L. Wilterdink, B. Bendixen, H. P. Adams Jr, R. F. Woolson, W. R. Clarke, and M. D. Hansen Effect of Prior Aspirin Use on Stroke Severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Stroke, December 1, 2001; 32(12): 2836 - 2840. [Abstract] [Full Text] [PDF]

				N. M Smith, R. Pathansali, and P. M. Bath Platelets and stroke Vascular Medicine, August 1, 1999; 4(3): 165 - 172. [Abstract] [PDF]

				M. T. Littleton-Kearney, P. D. Hurn, T. S. Kickler, and R. J. Traystman Incomplete global cerebral ischemia alters platelet biology in neonatal and adult sheep Am J Physiol Heart Circ Physiol, April 1, 1998; 274(4): H1293 - H1300. [Abstract] [Full Text] [PDF]

				T. Iwamoto, H. Kubo, and M. Takasaki Platelet Activation in the Cerebral Circulation in Different Subtypes of Ischemic Stroke and Binswanger's Disease Stroke, January 1, 1995; 26(1): 52 - 56. [Abstract] [Full Text]